| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue (including nil and 16,070 of revenue from related party for the period ended march 31, 2026 and 2025 respectively) | 22,842 | 483,760 | 2,543,823 | 2,260,253 |
| Cost of revenue | 23,632 | 487,743 | 2,166,138 | 1,892,231 |
| Gross (gain)/profit | -790 | -3,983 | 377,685 | 368,022 |
| Dividend income | 0 | 360 | 4,192 | 8,626 |
| Interest income | 17,179 | 9,774 | 20,778 | 29,768 |
| Fair value gain on investments in equity securities | 0 | -28,256 | 0 | 23,742 |
| Loss on disposal of investments in equity securities | NaN | 55,823* | 42,376 | 0 |
| Reversal of expected credit losses | 26,743 | 49,855 | 0 | 69,759 |
| Gain from foreign exchange | 5,617 | 23,666* | NaN | NaN |
| Others | 8,147 | -87,746 | 40,414 | 77,566 |
| Total other income | 57,686 | 23,476 | 107,760 | 209,461 |
| Sales and marketing | 52,733 | -3,663* | 551,569 | 608,427 |
| Research and development | 14,487 | 9,520.5* | 14,876 | 12,557 |
| General and administrative (including nil and 1,044 of rental expenses to related party for the period ended march 31, 2026 and 2025, respectively) | 327,669 | 91,730.5* | 445,691 | 516,790 |
| Share-based compensation | NaN | 3,036,466* | NaN | NaN |
| Fair value loss on investments in equity securities | 0 | 17,462* | 0 | 51,002 |
| Provision for expected credit losses | 202,497 | 7,484* | 175,818 | 0 |
| Total operating expenses | 597,386 | 3,159,000 | 1,187,954 | 1,188,776 |
| Loss from operations | -540,490 | -1,032,845 | -702,509 | -611,293 |
| Finance costs | 3,085 | 3,272 | 6,482 | 4,879 |
| Loss before tax | -543,575 | -1,036,117 | -708,991 | -616,172 |
| Deferred tax | NaN | 0* | NaN | NaN |
| Income tax | NaN | 0* | NaN | NaN |
| Tax expense | NaN | 0 | 0 | 0 |
| Net loss attributable to common shareholders | -543,575 | -1,036,117 | -708,991 | -616,172 |
| Foreign currency translation loss | 21,900 | -8,202 | 3,216 | 367,078 |
| Comprehensive loss | -521,675 | -1,044,319 | -705,775 | -249,094 |
| Diluted EPS | -0.225 | NaN | -0.395 | -0.343 |
| Diluted Average Shares | 2,417,314 | NaN | 1,796,597 | 1,796,597 |
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)